Combined radiofrequency and chemoembolization vs. chemoembolization in management of hepatocellular carcinoma

Abstract

Aim: Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. If left untreated, liver cancer has a poor prognosis with more than 90% of patients dying of the disease within 5 years of diagnosis. The aim of this study is to assess the value of combined radiofrequency ablation (RFA), followed by trans-arterial chemoembolization (TACE) in the management of HCC.

Methods: Fifty HCC patients with chronic liver disease were categorized into two groups according to the modality of locoregional treatment: 25 HCC patients treated with RFA followed by TACE within 5 days and 25 HCC patients treated with TACE only.

Results: Complete response was achieved in 100% and 84% of the HCC patients after 1 month from combined RFA-TACE therapy and TACE only respectively. The rate of objective response after 7 months was 84% and 44% in the RFA-TACE and TACE groups respectively. One year disease free survival rate was 56% and 24% in RFA-TACE and TACE groups respectively, and overall survival rate was 88% in the RFA-TACE group and 80% in the TACE only group.

Conclusion: Combined RFA-TACE appears to be an effective modality and superior to TACE only for the treatment of HCC.

Keywords

Hepatocellular carcinoma / radiofrequency / trans-arterial chemoembolization

References

[1] Parkin DM,Ferlay J.Global cancer statistics, 2002..CA Cancer J Clin2005;55:74-108

[2] el-Zayadi AR,Barakat EM,Shawky S,Selim O.Hepatocellular carcinoma in Egypt: a single center study over a decade..World J Gastroenterol2005;11:5193-8 PMCID:PMC4320394

[3] McGhana JP.Radiofrequency ablation of the liver: current status..AJR Am J Roentgenol2001;176:3-16

[4] Livraghi T,Lazzaroni S,Ierace T,Gazelle GS.Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions..Radiology2000;214:761-8

[5] Janis and Friends, Hepatitis C Support web site, Liver Cancer; 2008. Available from: http://www.janisandfriendshepatitiscsupport.com. [Last accessed on 2012 Oct 1]

[6] Kurokohchi K,Masaki T,Funaki T,Yoshida S,Kuriyama S.Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocelluar carcinoma..Int J Oncol2002;21:841-6

[7] Bruix J.Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma..Hepatology2005;42:1208-36

[8] Llovet JM,Bruix J.Hepatocellular carcinoma..Lancet2003;362:1907-17

[9] Mallick I. What is the performance status? Health Disease and Condition Content is reviewed by the Medical Review Board; 2007. Available from: http://www.About.com. [Last accessed on 2012 Oct 1].

[10] Mor E,Sheiner P.Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation..Ann Intern Med1998;129:643-53

[11] Okuda K,Obata H,Okazaki N,Nakajima Y.Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients..Cancer1985;56:918-28

[12] Al Knawy B,Bolondi L.Preface.In: Hepatocellular Carcinoma: a practical approach. United Kingdom: Informa Healthcare;2009;

[13] Velázquez RF,Navascués CA,Pérez R,Martínez I.Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis..Hepatology2003;37:520-7

[14] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival..Hepatology2003;37:429-42

[15] Miraglia R,Maruzzelli L,Caruso S,Mamone G,Luca A.Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma..World J Gastroenterol2007;13:2952-5 PMCID:PMC4171147

[16] N'Kontchou G,Aout M,Grando V,Vicaut E,Sellier N,Seror O.Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis..Hepatology2009;50:1475-83

[17] Takaki H,Nakatsuka A,Murata K,Takeda K.Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression..J Vasc Interv Radiol2007;18:856-61

[18] Rhim H,Choi D.Current status of radiofrequency ablation of hepatocellular carcinoma..World J Gastrointest Surg2010;2:128-36 PMCID:PMC2999222

[19] Yamakado K,Takaki H,Usui M,Isaji S,Fuke H,Takeda K.Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy..Radiology2008;247:260-6

[20] Peng ZW,Liang HH,Zhang YJ,Zhang YQ.A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma..Eur J Surg Oncol2010;36:257-63

[21] Wang YH,Li F,Liu Q,Liu DG.Radiofrequency ablation combined with transarterial chemoembolization for unresectable primary liver cancer..Chin Med J (Engl)2009;122:889-94

[22] Takaki H,Uraki J,Fuke H,Shiraki K,Takeda K.Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm..J Vasc Interv Radiol2009;20:217-24

[23] Cheng BQ,Liu CT,Wang QL,Yi CH.Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial..JAMA2008;299:1669-77

[24] Sacco R,Petruzzi P,Bargellini I,Federici G,Metrangolo S,Romano A,Tumino E,Altomare E,Capria A.Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study..World J Gastroenterol2009;15:1843-8 PMCID:PMC2670411

[25] Kim JH,Shin YM,Yoon HK,Kim PN.Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone..Ann Surg Oncol2011;18:1624-9

[26] Kagawa T,Kojima S,Numata M,Watanabe T.Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection..Cancer2010;116:3638-44